Clinical Trials

Inclusion Criteria: 

• Men or women ≥ 18 years of age.
• Diagnosis of definite oGVHD using the International Chronic Ocular GVHD Consensus Group Revised Diagnostic criteria in at least one eye. 
• Ocular Discomfort score ≥ 3. 
• Validated Bulbar Redness score ≥ 40 in both eyes.
• Subjects who are capable and willing to provide informed consent and follow study instructions.
• Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye. 
• Women who are not pregnant or lactating or post-menopausal or have undergone a sterilization procedure.

Exclusion Criteria: 

• Allergic to brimonidine or any similar products, or excipients of brimonidine. 
• Currently receiving any brimonidine or other treatment for glaucoma. 
• Receiving or have received any investigational drug or device within 30 days of screening.
• Current use of contact lenses 14 days prior to screening.
• Active ocular infection or ocular allergies. 
• Any history of eyelid surgery or ocular surgery within the past 3 months.
• Corneal epithelial defect larger than 1 mm (squared) in either eye.
• Received corticosteroid-containing eye drops within 14 days prior to screening or planned use during the study.
• Any change in corticosteroid-containing eye drops, systemic corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®) or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30 days prior to screening or planned change during the study.